Outcome of Preserved Mitral Valve Apparatus During Mitral Valve Replacement (EarlyOutcome)
Outcome of Preservation of Mitral Valve Leaflets During Mitral Replacement
Are there differences in outcome of mitral valve replacement with preservation of mitral apparatus among rheumatic and/or ischemic mitral lesions?.
Mitral valve replacement with preservation of leaflets, and added coronary artery-bypass surgery, when indicated, is it a feasible and reproducible procedure?.
The study was designed to compare outcome after prosthetic mitral replacement with preservation of mitral apparatus for rheumatic valve disease with outcome of replacement for ischemic myocardium and mitral valve disease, The outcomes will be guided by clinical assessment. and echo-cardiograph.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Objectives: The aim is to compare outcome of modified preservation of mitral valve apparatus during prosthetic mitral replacement for rheumatic versus myocardial ischemia &mitral valve disease.
Methods ;This prospective cross-sectional comparative study will include 50 patients with isolated rheumatic mitral valve disease (group A) and 50 patients with mitral disease and myocardial ischemia (group B), surgery is expected to be performed between 2017 and 2020 at one center. All patients will have modified preservation of mitral apparatus during prosthetic mitral replacement. Additionally, group B patients will have bypass grafts to left anterior descending and/or posterior descending / right coronary artery. Data will be collected and analyzed.
The Institutional Review Board (IRB), Ethics Committee (EC)-approval and consent of each patient were obtained.
Criteria for inclusion of patients and exclusion of others were determined according to the guide lines.
Statistical analysis::
Qualitative variables and their association among both groups were studied by applying Chi-square test and Fisher Exact test. Quantitative variables among both groups were compared by applying independent samples t-test. P < 0.05 values mean statistically-significant results.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Ismailia, Egypte, +064
- Suez Canal University
-
Ismailia, Egypte, 002-064
- Suez Canal University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria::
Mitral stenosis (MS)
- symptoms are severely limiting and cannot be managed with diuresis and heart rate control.
Mitral regurgitation(MR):
* acute severe MR require surgical correction for hemo-dynamics and relief of symptoms .
Chronic primary mitral regurgitation:
* rheumatic heart disease: replacement before irreversible changes occur can be curative.
Mixed Mitral Stenosis and Mitral Regurgitation:
- If beta blockers and diuretics do not relieve symptoms, replacement should be performed only in patients who have severe limiting symptoms.
- Myocardial ischemia associating or complicated with miral valve disease.
Exclusion criteria
- Patients showing good response to medical therapy, and Cases complicated by:
- ineffective endocarditis,
- previous myocardial re-vascularization
- ischemic ventricular septal defect,
- left ventricular aneurysm,
- Ruptured papillary muscles of mitral apparatus.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur factice: Group A
50 patients with isolated rheumatic mitral valve disease (group A)
|
St.Jude prosthetic(FDA approved) mitral valve replacement with or without coronary artery bypass grafts
Autres noms:
|
|
Autre: Group B
50 patients with mitral disease and myocardial ischemia (group B)
|
St.Jude prosthetic(FDA approved) mitral valve replacement with or without coronary artery bypass grafts
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Smoking index
Délai: One week before surgery(or during first clinical visit) .
|
Number of Packs every day X number of years of smoking= Pack.year,
|
One week before surgery(or during first clinical visit) .
|
|
Age and gender for each participant
Délai: One week before surgery .
|
Males above 40 years and Females above 45 years need pre-operative coronary angio-graph
|
One week before surgery .
|
|
For each participant: pathological:type of mitral valve lesion
Délai: Seven days before surgery .
|
severe stenosis with mitral area < 1 cm square, severe regurgitation, or mixed lesions
|
Seven days before surgery .
|
|
For each participant: etiological :type of mitral valve lesion
Délai: Seven days before surgery .
|
Rheumatic: distorted thickened leaflets,thickened fibrosed chordae
|
Seven days before surgery .
|
|
For each participant: etiological :type of mitral valve lesion
Délai: Seven days before surgery- echo-cardiograph.
|
Rheumatic: distorted thickened leaflets,thickened fibrosed chordae or ischemic incompetence
|
Seven days before surgery- echo-cardiograph.
|
|
For each participant:, assessing sub-valvular apparatus
Délai: One week before surgery. with Echo-cardiograph.
|
Thickened chordae, ruptured chordae, ischemia of papillary muscles or lateral ventricular wall.
|
One week before surgery. with Echo-cardiograph.
|
|
Abascal echo-cardiographic mitral valve score (Wilkins score)
Délai: One week before surgery.with Echo-cardiograph
|
:if score is 8 or less it is good for balloon valvo-plasty, if > 8 surgery is recommended ( leaflet mobility, thickness and calcification.
Fourthly, sub-valvular thickening., higher scores = more deterioration
|
One week before surgery.with Echo-cardiograph
|
|
left ventricular wall motion abnormality
Délai: one week before surgery - with an echo-cardiograph
|
hypokinesia, Akinesia, Dyskinesia of certain segment(s)
|
one week before surgery - with an echo-cardiograph
|
|
Number of participants with Signs of left ventricular dysfunction
Délai: seven days before surgery echo-cardiograph examination
|
low ejection fraction <52%, low stroke volume< 70 ml, low cardiac output <5 litres per minute
|
seven days before surgery echo-cardiograph examination
|
|
Number of participants with pre-operative coronary artery disease
Délai: seven days before surgery, coronary angio-graph
|
Expected on clinical bases and .proved
by Echo-cardiograph-findings
|
seven days before surgery, coronary angio-graph
|
|
Number of participants with pre-operative ischemic complications
Délai: seven days before surgery echo-cardiograph examination
|
left ventricular thrombi, septal and left ventricular wall thickness in mm .
|
seven days before surgery echo-cardiograph examination
|
|
Assessment of any evolving new prosthetic valve dysfunction
Délai: intra-operative trans-esophageal echo-cardiograph examination
|
Left atrioventricular outflow stenosis, prosthetic dysfunction due to preservation of valve apparatus
|
intra-operative trans-esophageal echo-cardiograph examination
|
|
Change in post-operative left ventricular functions
Délai: 5 days post-operatively and end of 6th and 12 months after surgery with Echo-Cardiograph
|
: Low Fractional Shortening < 28% , Ejection fraction < 40%,, increased left ventricular dimensions and volume
|
5 days post-operatively and end of 6th and 12 months after surgery with Echo-Cardiograph
|
|
Change of Prosthetic mitral valve functions
Délai: Monthly through study completion up to 12 months after surgery..... with Echo-cardiograph
|
Development of para-valvular leak or central jet of regurgitation or stuck valve by a thrombus
|
Monthly through study completion up to 12 months after surgery..... with Echo-cardiograph
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
changes on Clinical examination
Délai: Monthly up to 12 months after surgery)
|
local and general Examination,: a new murmur, evolving heart failure
|
Monthly up to 12 months after surgery)
|
|
Changes in Results of Prothrombin time, concentration and.International normalized ratio
Délai: .Monthly through study completion up to 12 months.
|
Adjust dose of oral anticoagulant.( between double and half to three times the control) Dose usually ranges between 1 and 11 mg warfarin tablet daily.
|
.Monthly through study completion up to 12 months.
|
|
Mortality and Morbidity
Délai: Monthly through study completion up to 12 months.
|
cause of mortality, type of morbidity: wound infection, hypertrophied scar, Kiloid Formation
|
Monthly through study completion up to 12 months.
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Directeur d'études: Mohamed A. allaban, PhD, Suez Canal University, FOM- Research Ethics Committee
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2796#
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Délai de partage IPD
Critères d'accès au partage IPD
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .